SILVER SPRING, Md. - Members of the FDA's Oncologic Drug Advisory Committee on Thursday agreed to some degree with recent label changes to Amgen Inc.'s blockbuster EPO products, but also suggested a few further steps, proposing more studies and stricter guidelines on prescribing the red blood cell boosters. (BioWorld Today)